SCM
BHVN

Soleus Capital Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Soleus Capital Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-7,661
Closed -$657K – 90
2020
Q4 		$657K Buy
+7,661
New +$649K 0.09% 58
2020
Q3 		– Sell
-14,000
Closed -$1.02M – 80
2020
Q2 		$1.02M Buy
+14,000
New +$745K 0.58% 39

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Soleus Capital Management's BHVN Position: Q1 2021 in Review

Soleus Capital Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2021, closing a stake of 7,661 shares — an estimated $657K sold.

Soleus Capital Management first reported a position in BHVN in Q2 2020 and held it in 2 quarters. The position peaked at $1.02M in Q2 2020. 224 funds tracked by Wall St. Rank hold BHVN as of Q1 2021.

  • Soleus Capital Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2021 after selling out during the quarter.
  • Soleus Capital Management sold 7,661 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2021, an estimated $657K.
  • Soleus Capital Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2020 and held it in 2 quarters.
  • Soleus Capital Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.02M in Q2 2020.
  • 224 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2021.

Based on Soleus Capital Management's 13F filing for Q1 2021, filed 17 May 2021.